Maria Månsson Martinez, Lampros Spiliopoulos, Falastin Salami, Daniel Agardh, Jorma Toppari, Åke Lernmark, Jukka Kero, Riitta Veijola, Päivi Tossavainen, Sauli Palmu, Markus Lundgren, Henrik Borg, Anastasia Katsarou, Helena Elding Larsson, Mikael Knip, Marlena Maziarz, Carina Törn
BACKGROUND: Individuals with multiple islet autoantibodies are at increased risk for clinical type 1 diabetes and may proceed gradually from stage to stage complicating the recruitment to secondary prevention studies. We evaluated multiple islet autoantibody positive subjects before randomisation for a clinical trial 1 month apart for beta-cell function, glucose metabolism and continuous glucose monitoring (CGM). We hypothesized that the number and type of islet autoantibodies in combination with different measures of glucose metabolism including fasting glucose, HbA1c, oral glucose tolerance test (OGTT), intra venous glucose tolerance test (IvGTT) and CGM allows for more precise staging of autoimmune type 1 diabetes than the number of islet autoantibodies alone...
January 5, 2022: Clinical Diabetes and Endocrinology